- •
Fractures and osteoporosis are common, especially in the elderly population. Hip fractures may be devastating.
- •
Osteoporosis in men is greatly unrecognized and untreated.
- •
Treatment of osteoporosis is generally recommended in postmenopausal women and men 50 years old or older who have a bone mineral density T score of −2.5 or less, a history of previous spine or hip fracture, or a Fracture Risk Assessment Tool score indicating increased fracture risk.
- •
Bisphosphonates, teriparatide and denosumab have
A Review of Osteoporosis in the Older Adult
Section snippets
Key points
Summary
Current approaches to the treatment of osteoporosis are based on BMD and fracture risk assessment. Bisphosphonates are typically the first-line agents. A treatment failure is considered when significant loss in BMD is seen or the patient sustains a fracture despite ongoing treatment. A drug holiday is considered after 3 to 5 years of bisphosphonate treatment. Goal-directed treatment has been recently proposed based on BMD or fracture risk assessment using the FRAX tool in order to aim for a
References (70)
- et al.
Mortality after all major types of osteoporotic fracture in men and women: an observational study
Lancet
(1999) - et al.
Rehabilitation of the older adult with an osteoporosis-related fracture
Clin Geriatr Med
(2006) - et al.
A reference standard for the description of osteoporosis
Bone
(2008) - et al.
Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: a 12-month randomized, clinical trial
Bone
(2015) - et al.
Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Lancet
(1996) - et al.
Efficacy and safety of currently marketed antiosteoporosis medications
Best Pract Res Clin Endocrinol
(2014) - et al.
Effect of Denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial
Bone
(2008) - et al.
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
Lancet
(2015) - et al.
Individualizing osteoporosis therapy
Osteoporos Int
(2012) - et al.
Risk of nursing home admission after femoral fracture compared with stroke, myocardial infarction, and pneumonia
J Am Med Dir Assoc
(2015)
Osteoporosis medication use after hip fracture in U.S. Patients between 2002 and 2011
J Bone Miner Res
Minireview: the OPG/RANKL/RANK system
Endocrinology
The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?
J Bone Miner Res
Current approaches to osteoporosis treatment
Curr Opin Rheumatol
Understanding the mechanisms of senile osteoporosis: new facts for a major geriatric syndrome
J Am Geriatr Soc
Undertreatment of osteoporosis in men with hip fractures
Arch Intern Med
The near absence of osteoporosis treatment in older men with fractures
Osteoporos Int
Observations on nursing home patient with history of hip fracture
Am J Med Sci
Osteoporosis in men
N Engl J Med
Long-term effect of testosterone therapy on bone mineral density in hypogonadal men
J Clin Endocrinol Metab
Clinician’s guide to prevention and treatment of osteoporosis
Osteoporos Int
Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement
Ann Intern Med
Osteoporosis in men: an Endocrine Society clinical practice guideline
J Clin Endocrinol Metab
FRAX underestimates fracture risk in patients with diabetes
J Bone Miner Res
Continuing bisphosphonate treatment for osteoporosis–for whom and for how long?
N Engl J Med
Postmenopausal osteoporosis
N Engl J Med
Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study
J Clin Endocrinol Metab
Comparative effectiveness of drug treatments to prevent fragility fractures: a systemic review and network meta-analysis
J Clin Endocrinol Metab
Calcium plus vitamin D supplementation and the risk of fractures
N Engl J Med
Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone
J Clin Endocrinol Metab
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial
JAMA
Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk
J Natl Cancer Inst
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial
JAMA
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial
JAMA
Cited by (0)
Disclosure Statement: The authors have nothing to disclose.